Lexaria Bioscience Corp.
LEXX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.92
KIRA · Stoqly’s AI analyst, in plain words
- Lexaria Bioscience Corp. had $0.7M of revenue in fiscal 2025, up 52.0% on the year before. Over five years, revenue changed +17.5% a year on average.
- Its operating margin was −1,683.1%, down 444.0 pts: of every 100 in sales, about −1,683 is left after running the business.
- Lexaria Bioscience Corp. lost $11.9M in fiscal 2025.
- Free cash flow was −$10.5M in fiscal 2025, −1,483.9% of revenue.
Market cap
$72.4M
P/E
—
Revenue
$0.7M
Net income
−$11.9M
Free cash flow
−$10.5M
Operating margin
−1,683.1%
Lexaria Bioscience Corp. in 30 seconds · fiscal 2025
Are sales growing?
+52.0%
Yes. Sales grew 52.0% last year.
Does it make a profit?
−1,686.0%
No. It lost money last year.
Does profit turn into cash?
−1,483.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lexaria Bioscience Corp. does
No business description yet.
- Fiscal year ends
- August 31, 2025
- Latest annual report
- 10-K · Nov 28, 2025
- Legal name
- Lexaria Bioscience Corp.
- CIK
- 0001348362
Lexaria Bioscience Corp. · LEXX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.7M | $0.3M | $0.2M | $0.5M | $0.7M |
| Revenue growth | 129.6% | −64.7% | −11.4% | 105.3% | 52.0% |
| Net interest income | — | — | $0.0M | $0.0M | — |
| Gross margin | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| Operating margin | −786.9% | −2,591.6% | −2,888.6% | −1,239.1% | −1,683.1% |
| Net income | −$4.0M | −$7.3M | −$6.7M | −$5.8M | −$11.9M |
| Net margin | −557.2% | −2,846.2% | −2,946.5% | −1,248.2% | −1,686.0% |
| Diluted EPS | −$0.95 | — | −$1.01 | −$0.47 | −$0.66 |
| Cash | |||||
| Cash from operations | −$4.0M | −$4.9M | −$5.9M | −$5.0M | −$10.5M |
| Capital expenditure | — | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | — | −$4.9M | −$5.9M | −$5.0M | −$10.5M |
| FCF margin | — | −1,929.7% | −2,614.9% | −1,077.3% | −1,483.9% |
| Share count change | 58.3% | — | — | 87.2% | 45.3% |
| Debt and strength | |||||
| Cash and short-term investments | $11.8M | $6.2M | $1.5M | $6.6M | $1.9M |
| Shareholders' equity | $13.1M | $7.9M | $3.0M | $8.0M | $3.0M |
| Current ratio | 81.2x | 36.0x | 8.0x | 7.2x | 2.3x |
| Returns and quality | |||||
| Return on equity | −51.8% | −69.2% | −121.3% | −104.6% | −215.9% |
| Return on tangible equity | −30.8% | −91.5% | −258.2% | −77.1% | −443.8% |
| Piotroski F-score | 4 | 1 | 3 | 3 | 3 |
| Altman Z'' | 62.8 | 25.2 | −50.7 | −11.3 | −63.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lexaria Bioscience Corp. · LEXX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.92 a share, the company is worth $72.4M.
Source: SEC EDGAR XBRL filings (CIK 0001348362). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.